Corcept Therapeutics Incorporated (CORT)
Automate Your Wheel Strategy on CORT
With Tiblio's Option Bot, you can configure your own wheel strategy including CORT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CORT
- Rev/Share 7.158
- Book/Share 6.1027
- PB 5.9564
- Debt/Equity 0.0101
- CurrentRatio 3.1413
- ROIC 0.1005
- MktCap 3823581169.0
- FreeCF/Share 1.57
- PFCF 23.5202
- PE 35.7831
- Debt/Assets 0.0077
- DivYield 0
- ROE 0.1599
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 1
- DCF Score 5
- P/B Score 1
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CORT | Wolfe Research | Peer Perform | Underperform | -- | $30 | Dec. 31, 2025 |
| Initiation | CORT | UBS | -- | Neutral | -- | -- | Dec. 16, 2025 |
| Initiation | CORT | Wolfe Research | -- | Peer Perform | -- | -- | Nov. 18, 2025 |
News
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% – Hagens Berman
Published: January 09, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter (“CRL”) from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant.
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Published: January 08, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK, Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation Into Corcept Therapeutics Incorporated (CORT)
Published: January 07, 2026 by: Newsfile Corp
Sentiment: Neutral
New York, New York--(Newsfile Corp. - January 7, 2026) - Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a shareholder and consumer rights litigation firm, is investigating whether Corcept Therapeutics Incorporated ("Corcept" or the "Company") (NASDAQ: CORT) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws. CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS POTENTIAL CLASS ACTION Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders.
Read More
Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman
Published: January 06, 2026 by: PRNewsWire
Sentiment: Neutral
SAN FRANCISCO, Jan. 6, 2026 /PRNewswire/ -- Investors in Corcept Therapeutics Incorporated (NASDAQ: CORT) saw the price of their shares crater 50% on December 31, 2025 after the company announced its receipt of a complete response letter ("CRL") from the FDA for its proposed treatment of patients with hypercortisolism (also known as Cushing's syndrome) – relacorilant. The news and severe market reaction has prompted national shareholder rights law firm Hagens Berman to commence an investigation into whether Corcept may have misled investors about relacorilant's efficacy and commercial prospects.
Read More
Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains?
Published: January 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism
Published: January 02, 2026 by: Zacks Investment Research
Sentiment: Negative
CORT's shares plunge after the FDA issues a CRL to relacorilant's new drug application for treating patients with hypercortisolism.
Read More
Corcept Therapeutics' Upcoming FDA Decision: Is A CRL Likely?
Published: December 22, 2025 by: Benzinga
Sentiment: Negative
Are There Red Flags in the Trial Results?
Read More
Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue?
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
Read More
Will Korlym Continue to Drive Corcept's Top Line in 2026?
Published: December 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
CORT leans on rising Korlym sales while awaiting key relacorilant FDA decisions that could broaden its growth path in 2026.
Read More
Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
CORT's third-quarter earnings and sales miss estimate. The company cuts guidance despite a 14% year-over-year rise in revenues.
Read More
Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for
Published: October 22, 2025 by: Zacks Investment Research
Sentiment: Negative
Corcept (CORT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer
Published: October 15, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept files a marketing application with the EMA for relacorilant in platinum-resistant ovarian cancer after studies show survival gains.
Read More
Corcept Transition To New Specialty Pharmacy Well Underway
Published: October 15, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics (CORT) has added Curant Rare as a second specialty pharmacy to handle increased prescription demand for Korlym. Optime Care will discontinue servicing CORT prescriptions due to its preference for exclusive partnerships, causing some market confusion. CORT management and sell-side analysts confirm Curant Health is smoothly processing all new prescription growth, ensuring continuity.
Read More
Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym?
Published: October 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Corcept expects relacorilant to ease sole reliance on Korlym for revenues. Relacorilant is under FDA review for Cushing's syndrome and ovarian cancer.
Read More
Corcept Primed For An Upside EPS Surprise
Published: September 26, 2025 by: Seeking Alpha
Sentiment: Positive
My September quarter EPS forecast of $0.29 for Corcept could meaningfully beat analyst projections of $0.17. Approval of the company's Relacorilant medication by the FDA will essentially resolve any generic threat of its current medication, Korlym. Corcept's patient base has increased from about 10,000 to over 1 million hard-to-treat diabetics.
Read More
Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025
Published: September 22, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 European Society for Medical Oncology.
Read More
FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer
Published: September 11, 2025 by: Zacks Investment Research
Sentiment: Positive
CORT's NDA for relacorilant in platinum-resistant ovarian cancer gains FDA acceptance, with a decision expected by July 2026.
Read More
Can Korlym Drive Corcept's Growth Through the Rest of 2025?
Published: September 02, 2025 by: Zacks Investment Research
Sentiment: Neutral
CORT projects $850-$900M in 2025 revenues as Korlym sales rise and relacorilant nears an FDA decision for Cushing's syndrome.
Read More
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
Published: August 25, 2025 by: Zacks Investment Research
Sentiment: Positive
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Read More
Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q2 2025 Earnings Call July 31, 2025 5:00 PM ET Company Participants Atabak Mokari - CFO & Treasurer Gary Charles Robb - Chief Business Officer & Secretary Joseph K. Belanoff - Co-Founder, President, CEO & Director Roberto W.
Read More
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Neutral
Corcept beats second-quarter earnings forecasts but misses the same for revenues. The company trims its 2025 revenue outlook.
Read More
Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
CORT's relacorilant combo targets platinum-resistant ovarian cancer in new NDA, backed by positive ROSELLA study data.
Read More
Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
Published: July 14, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, has submitted a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for its proprietary, selective cortisol modulator, relacorilant, to treat patients with platinum-resistant o.
Read More
Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting
Published: June 05, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, presented results from its DAZALS study of dazucorilant in patients with ALS at the European Network to Cure ALS (ENCALS) 2025 annual meeting. The presentation can be found here. DAZALS is a randomi.
Read More
CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
Corcept's first-quarter 2025 earnings meet estimates while revenues miss the same. The company reiterates its revenue guidance for 2025.
Read More
Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Corcept Therapeutics Incorporated (NASDAQ:CORT ) Q1 2025 Earnings Conference Call May 5, 2025 5:00 PM ET Company Participants Atabak Mokari - Chief Financial Officer Sean Maduck - President, Endocrinology Charlie Robb - Chief Business Officer Joe Belanoff - Chief Executive Officer Roberto Vieira - President, Oncology Bill Guyer - Chief Development Officer Conference Call Participants Edward Nash - Canaccord David Amsellem - Piper Sandler Joon Lee - Truist Securities RK - H. C. Wainwright Operator Thank you for standing by.
Read More
CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025
Published: April 23, 2025 by: Business Wire
Sentiment: Neutral
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the 2025 American Society of Clinical Oncology (ASC.
Read More
Does Corcept (CORT) Have the Potential to Rally 28.63% as Wall Street Analysts Expect?
Published: April 02, 2025 by: Zacks Investment Research
Sentiment: Positive
The average of price targets set by Wall Street analysts indicates a potential upside of 28.6% in Corcept (CORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Read More
Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release
Published: April 01, 2025 by: Seeking Alpha
Sentiment: Positive
Corcept Therapeutics Incorporated's relacorilant met the primary endpoint in the phase 3 ROSELLA study for platinum-resistant ovarian cancer patients, boosting shares by over 90% the very same day. Upcoming catalysts include full trial data release at a medical conference, NDA filing in Q3 2025, and MAA submission to the EMA shortly afterward. Relacorilant also targets hypercortisolism with endogenous Cushing's Syndrome patients with an FDA PDUFA date set for December 30, 2025, based on positive GRACE, GRADIENT, and phase 2 study data.
Read More
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
Published: April 01, 2025 by: Zacks Investment Research
Sentiment: Positive
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
Read More
About Corcept Therapeutics Incorporated (CORT)
- IPO Date 2004-04-14
- Website https://www.corcept.com
- Industry Biotechnology
- CEO Joseph K. Belanoff
- Employees 500